Arcutis Biotherapeutics (ARQT) - Cash Funds Calculated per Share

Corporate emblem and logo of Arcutis Corp (ARQT)

The cash per share chart demonstrates the impact of geopolitical risks hindering logistics and new drug testing, with the metric holding around 2.04. Arcutis Biotherapeutics (ARQT) relies on strong pricing power by adapting biologics into safe creams. Successful sales of the psoriasis product line have stabilized the balance sheet, halting the rapid depletion of the company's cash reserves.

Arcutis (ARQT) Cash per Single Share: for the period 07/04/2022 - 11/20/2026

Comprehensive metric breakdowns and analytics for Arcutis (ARQT)

- share price and consensus valuation forecast:
- cash position and cash flow details:
Comprehensive company analysis:ARQT (Arcutis Biotherapeutics)
Brand item of Arcutis Biotherapeutics, Inc.

The high margins of Arcutis Biotherapeutics (ARQT) unique non-steroidal treatments require significant reserves to scale expansion, which reflects the importance of cash per share. This indicator, calculated as the ratio of liquid assets to the number of issued shares, determines the volume of the financial buffer per share, allowing investors to assess the company's resilience to capital shortages without resorting to costly loans.